The Company intends to expand its solid operational base with the acquisition of stem cell and related companies which products and services are complimentary to the current portfolio and will further strengthen the company and generate value for shareholders.
It will establish a worldwide “centre of excellence” in stem cell medicine in the Bahamas and intends to expand to other areas in the world.
The Company continues investing into researching and treating a variety of diseases with mesenchymal stem cells and their paracrine substances. One focus will be on Neurodegenerative diseases, the largest medical, social and socio-economical challenge of our time. Preclinical and clinical trials for Alzheimer Disease, Dementia and Parkinson Disease are being prepared and registration as ATMP (advanced therapy medicinal product) as well as autologous treatments is envisaged.